eShowcase: Laboratory and Clinical Study Status
Secure Web-based Test Article Submissions and Study Tracking Availale
Secure Web-based Test Article Submissions and Study Tracking Available
BioReliance (Rockville, MD), a contract services organization, announces a Web-based proprietary software system called iNet. iNet allows customers to submit test article details via controlled and secure Internet access. Clients can then view the status of current and past studies, keep informed of expected completion dates, download reports, and share information with colleagues to view testing status.
iNet from BioReliance
Components of iNet include projected lab initiation and report completion dates, which help to facilitate planning efforts. Electronic templates are also included for sample submissions to manage timelines and simplify processes. The product is compliant with 21 CFR Part 11 for user authentication. Data exchange is protected by Secured Sockets Layer certificates from VeriSign.
BioReliance, (301) 610-2544, www.bioreliance.com
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
